Neurizon Therapeutics to Release Shares from Escrow

Pharmaust Limited ( (AU:NUZ) ) has provided an announcement.

Neurizon Therapeutics Limited announced the release of 675,676 fully paid ordinary shares from voluntary escrow, scheduled for June 24, 2025, in compliance with ASX Listing Rule 3.10A. This move reflects the company’s ongoing efforts to manage its securities and could potentially impact its market operations and stakeholder interests.

The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.

More about Pharmaust Limited

Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative diseases. The company is advancing its lead drug candidate, NUZ-001, aimed at treating ALS, the most common form of motor neuron disease. Neurizon’s strategy involves accelerating access to effective ALS treatments and exploring broader applications for NUZ-001 through international collaborations and rigorous clinical programs.

YTD Price Performance: -5.88%

Average Trading Volume: 351,674

Technical Sentiment Signal: Buy

Current Market Cap: A$78.77M

Find detailed analytics on NUZ stock on TipRanks’ Stock Analysis page.